Profile

Perry Shen, M.D.Wake Forest Baptist Health

Doctor Rating

4.6 out of 5

214 Ratings
24 Comments

Perry Shen, M.D.

Program Director,
Professor,

Clinical Interests

Sarcoma, Hepatobiliary Surgery, Minimally Invasive Liver and Pancreatic Resection, Gastrointestinal Oncology Surgery, Peritoneal Surface Malignancies, Pancreatic Surgery, Melanoma

Contact Information

New Patient Appointments: 336-716-WAKE
Returning Patient Appointments: 336-716-4276
Department: 336-716-0545

Email: pshen@wakehealth.edu

Insurance Accepted »

Media Medical Expert »

Education & Training

  • B.S., University of California-Irvine, 1988
  • B.A., University of California-Irvine, 1988
  • M.D., University of Southern California Sch of Medicine, 1992
  • Internship, Obstetrics & Gynecology, J Hopkins-Balti Cty Hosps, 1993
  • Residency, Surgery, U Southern Calif Affil Hosps, 1998
  • Fellowship, John Wayne Cancer Institute, 2000

Board Certifications

  • American Board of Surgery, Surgery

Memberships

  • Am Assn Of Cancer Research
  • North Carolina Medical Assn
  • North Carolina Surgical Assn
  • Soc for Sur Of Alimentary Trac
  • Soc Of Surgical Oncology
  • Southeastern Surgical Congress
  • Southern Surgical Society
  • Society of Graduate Surgeons
  • Am Hepato-Pancreato-Biliary
  • Am Coll Of Surgeons
  • Am Medical Assn
  • Am Soc of Clinical Oncology
  • Assn Of Academic Surgery
  • Forsyth-Davie-Stokes Medical S

NPI Number

  • 1417932575
Perry Shen, M.D.

Doctor Rating

4.6 out of 5

214 Ratings
24 Comments

Perry Shen, M.D.

Program Director, Surgical Oncology
Professor, General Surgery
Comprehensive Cancer Center

Research Interests

cancer/oncogenesis

Contact Information

Academic: 336-716-0545 | Department: 336-716-0545

Email: pshen@wakehealth.edu

Media Medical Expert »

Recent Publications

Doud AN, Randle RW, Clark CJ, Levine EA, Swett KR, Shen P, Stewart JH, Votanopoulos KI. Impact of distal pancreatectomy on outcomes of peritoneal surface disease treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2015;22(5):1645-1650.

Randle RW, Doud AN, Levine EA, Clark CJ, Swett KR, Shen P, Stewart JH, Votanopoulos KI. Peritoneal surface disease with synchronous hepatic involvement treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2015;22(5):1634-1638.

Votanopoulos KI, Russell G, Randle RW, Shen P, Stewart JH, Levine EA. Peritoneal surface disease (PSD) from appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): overview of 481 cases. Ann Surg Oncol. 2015;22(4):1274-1279.

Randle RW, Ahmed S, Levine EA, Fino NF, Swett KR, Stewart JH, Shen P, Votanopoulos KI. Significance of diabetes on morbidity and mortality following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. J Surg Oncol. 2015;111(6):740-745.

Randle RW, Griffith KF, Fino NF, Swett KR, Stewart JH IV, Shen P, Levine EA, Votanopoulos KI. Appendiceal goblet cell carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Surg Res. 2015;196(2):229-234.

Slocum K, Adams L, Shen P, Griffith K, Allen S, Fino N, DeRoche A. Thoracic epidural versus intravenous patient controlled analgesia in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancy [abstract]. In: Abstracts of the 14th Annual ASRA Pain Medicine Meeting; 2015 May 14-16; Las Vegas (NV). 2015;():A530.

Doud AN, Levine EA, Fino NF, Stewart JH, Shen P, Votanopoulos KI. Stoma creation and reversal after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2015;():.

Levine EA, Stewart JH IV, Shen P, Russell GB, Loggie BL, Votanopoulos KI. Intraperitoneal chemotherapy for peritoneal surface malignancy: experience with 1,000 patients. J Am Coll Surg. 2014;218(4):573-585.

Votanopoulos KI, Randle RW, Craven B, Swett KR, Levine EA, Shen P, Stewart JH, Mirzazadeh M. Significance of urinary tract involvement in patients treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2014;21(3):868-874.

Randle RW, Swett KR, Swords DS, Shen P, Stewart JH, Levine EA, Votanopoulos KI. Efficacy of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in the management of malignant ascites. Ann Surg Oncol. 2014;21(5):1474-1479.

Trottman P, Swett K, Shen P, Sirintrapun J. Comparison of standard distal pancreatectomy and splenectomy with radical antegrade modular pancreatosplenectomy. Am Surg. 2014;80(3):295-300.

Blackham AU, Swett K, Eng C, Sirintrapun J, Bergman S, Geisinger KR, Votanopoulos K, Stewart JH, Shen P, Levine EA. Perioperative systemic chemotherapy for appendiceal mucinous carcinoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Surg Oncol. 2014;109(7):740-745.

Ahmed S, Levine EA, Swett KR, Randle RW, Shen PW, Stewart JH, Votanopoulos KI. Significance of diaphragmatic resections and thoracic chemoperfusion on outcomes of peritoneal surface disease treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) [abstract]. Ann Surg Oncol. 2014;21(Suppl 1):S135.

Randle RW, Swett KR, Stewart JH, Shen P, Levine EA, Votanopoulos KI. Morbidity and mortality following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in patients with diabetes [abstract]. Ann Surg Oncol. 2014;21(Suppl 1):S87.

Turaga K, Levine E, Barone R, Sticca R, Petrelli N, Lambert L, Nash G, Morse M, Adbel-Misih R, Alexander HR, Attiyeh F, Bartlett D, Bastidas A, Blazer T, Chu Q, Chung K, Dominguez-Parra L, Espat NJ, Foster J, Fournier K, Garcia R, Goodman M,. Consensus guidelines from The American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States. Ann Surg Oncol. 2014;21(5):1501-1505.

Sirintrapun SJ, Blackham AU, Russell G, Votanopoulos K, Stewart JH, Shen P, Levine EA, Geisinger KR, Bergman S. Significance of signet ring cells in high-grade mucinous adenocarcinoma of the peritoneum from appendiceal origin. Hum Pathol. 2014;45(8):1597-1604.

Blackham AU, Russell GB, Stewart JH IV, Votanopoulos K, Levine EA, Shen P. Metastatic colorectal cancer: survival comparison of hepatic resection versus cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2014;21(8):2667-2674.

Shen P, Thomas CR, Fenstermaker J, Aklilu M, McCoy TP, Levine EA. Phase II trial of adjuvant oral thalidomide following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface disease from colorectal/appendiceal cancer. J Gastrointest Cancer. 2014;45(3):268-275.

Ahmed S, Levine EA, Randle RW, Swett KR, Shen P, Stewart JH, Votanopoulos KI. Significance of diaphragmatic resections and thoracic chemoperfusion on outcomes of peritoneal surface disease treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2014;21(13):4226-4231.

Randle RW, Levine EA, Clark CJ, Stewart JH, Shen P, Votanopoulos KI. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for gallbladder cancer: a retrospective review. Am Surg. 2014;80(7):710-713.

Ahmed S, Shen P, Clark CJ.. Spigelain hernia with gallstone ileus: what are the chances?. Am Surg. 2014;80(8):E227-E229.

Caserta MP, Sakala M, Shen P, Gorden L, Wile G. Presurgical planning for hepatobiliary malignancies: clinical and imaging considerations. Magn Reson Imaging Clin N Am. 2014;22(3):447-465.

Ahmed S, Stewart JH, Shen P, Votanopoulos KI, Levine EA. Outcomes with cytoreductive surgery and HIPEC for peritoneal metastasis. J Surg Oncol. 2014;110(5):575-584.

Bryan ML, Fitzgerald NC, Levine EA, Shen P, Stewart JH, Votanopoulos KI. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in sarcomatosis from gastrointestinal stromal tumor. Am Surg. 2014;80(9):890-895.

Allen BC, Shen P. Peritoneal carcinomatosis: radiologic diagnosis In: Esquivel J, ed. Advances in the management of peritoneal carcinomatosis. London England: Unitec House;2014: 16-30.

Votanopoulos K, Ihemelandu C, Shen P, Stewart J, Russell G, Levine EA. A comparison of hematologic toxicity profiles after heated intraperitoneal chemotherapy with oxaliplatin and mitomycin C. J Surg Res. 2013;179(1):e133-e139.

Addington E, Russell G, Tedeschi R, Levine E, Shen P, Stewart J, Danhauer S, Duckworth K, McQuellon R. Post-traumatic growth is sustained two years after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy [abstract]. Psychooncology. 2013;22(Suppl 2):54.

Sirintrapun J, Blackham A, Russell G, Stewart J, Shen P, Levine E, Geisinger K, Bergman S, Cimic A. Significance of signet-ring cells in extracellular mucin pools versus tissue in high-grade mucinous carcinoma peritonei [abstract]. Lab Invest. 2013;93(Suppl 1):180A.

Votanopoulos KI, Swett K, Blackham AU, Ihemelandu C, Shen P, Stewart JH, Levine EA. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from rectal cancer. Ann Surg Oncol. 2013;20(4):1088-1092.

Ihemelandu C, Levine EA, Aklilu M, Yacoub G, Howerton R, Bolemon B, Graham M, Russell G, Shen P. Optimal timing of systemic therapy in resectable colorectal liver metastases. Am Surg. 2013;79(4):414-421.

Duckworth K, McQuellon R, Russell G, Campbell C, Shen P, Stewart J IV, Levine E. Patient preparedness and treatment satisfaction following cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (CS+HIPEC) [abstract]. Psychooncology. 2013;22(Suppl 2):54-55.

Howard-McNatt M, Lawrence J, Melin SA, Levine EA, Shen P, Stewart JH IV. Race and recurrence in women who undergo neoadjuvant chemotherapy for breast cancer. Am J Surg. 2013;205(4):397-401.

Blackham A, Swett K, Eng C, Sirintrapun J, Bergman S, Geisinger K, Votanopoulos KI, Stewart JH, Shen P, Levine E. Perioperative systemic chemotherapy for metastatic appendiceal cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy [abstract]. Ann Surg Oncol. 2013;20(Suppl 1):S13.

Newman NA, Lucas JT, Peacock DA, Trottman PA, Wentworth SS, Winters SM, Levine E, Shen P. Predictors for readmission after pancreatic resection for malignancy [abstract]. Ann Surg Oncol. 2013;20(Suppl 1):S140.

Randle RW, Swett KR, Shen P, Stewart JH, Levine EA, Votanopoulos KI. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in peritoneal sarcomatosis. Am Surg. 2013;79(6):620-624.

Sun Y, Shen P, Stewart JH, Russell GB, Levine EA. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from small bowel adenocarcinoma. Am Surg. 2013;79(6):644-648.

Votanopoulos KI, Swett K, Swords DS, Shen P, Stewart JH, Levine E. Obesity and peritoneal surface disease outcomes following cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) [abstract]. Ann Surg Oncol. 2013;20(Suppl 1):S113.

Blackham AU, Farrah JP, McCoy TP, Schmidt BS, Shen P. Prevention of surgical site infections in high-risk patients with laparotomy incisions using negative-pressure therapy. Am J Surg. 2013;205(6):647-654.

Ihemelandu CU, McQuellon R, Shen P, Stewart JH, Votanopoulos K, Levine EA. Predicting postoperative morbidity following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CS+HIPEC) with preoperative FACT-C (Functional Assessment of Cancer Therapy) and patient-rated performance status. Ann Surg Oncol. 2013;20(11):3519-3526.

Votanopoulos KI, Newman NA, Russell G, Ihemelandu C, Shen P, Stewart JH, Levine EA. Outcomes of cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients older than 70 years; survival benefit at considerable morbidity and mortality. Ann Surg Oncol. 2013;20(11):3497-3503.

Votanopoulos KI, Swords DS, Swett KR, Randle RW, Shen P, Stewart JH, Levine EA. Obesity and peritoneal surface disease: outcomes after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for appendiceal and colon primary tumors. Ann Surg Oncol. 2013;20(12):3899-3904.

Mann GN, Mann LV, Levine EA, Shen P. Primary leiomyosarcoma of the inferior vena cava: a 2-institution analysis of outcomes. Surgery. 2012;151(2):261-267.

Howard-McNatt M, Geisinger KR, Stewart JH IV, Shen P, Levine EA. Is intraoperative imprint cytology evaluation still feasible for the evaluation of sentinel lymph nodes for lobular carcinoma of the breast?. Ann Surg Oncol. 2012;19(3):929-934.

Craven B, Shen P, Levine E, Votanopoulos K, Stewart J, Mirzazadeh M. Urologic recostructive [sic] procedures in cytoreductive surgery (CRS) and intraperitoneal hyperthermic chemotherapy (HIPEC) for peritoneal surface malignancy in 934 consecutive procedures [abstract]. Neurourol Urodyn. 2012;31(2):287.

McQuellon R, Duckworth K, Russell G, Shen P, Stewart J, Votanopoulos K, Levine E. After screening for depression in a high risk medical population: then what? [abstract]. Psychooncology. 2012;21(Suppl 1):126-127.

Levine EA, Blazer DG III, Kim MK, Shen P, Stewart JH IV, Guy C, Hsu DS. Gene expression profiling of peritoneal metastases from appendiceal and colon cancer demonstrates unique biologic signatures and predicts patient outcomes. J Am Coll Surg. 2012;214(4):599-607.

Cao C, Yan TD, Deraco M, Elias D, Glehen O, Levine EA, Moran BJ, Morris DL, Chua TC, Piso P, Sugarbaker PH, Baratti D, Kusamura S, Gilly FN, Shen P, Mohamed F. Importance of gender in diffuse malignant peritoneal mesothelioma. Ann Oncol. 2012;23(6):1494-1498.

Duckworth KE, McQuellon RP, Russell GB, Cashwell CS, Shen P, Stewart JH IV, Levine EA. Patient rated outcomes and survivorship following cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (CS + HIPEC). J Surg Oncol. 2012;106(4):376-380.

Newman NA, Votanopoulos KL, Stewart JH, Shen P, Levine EA. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer. Minerva Chir. 2012;67(4):309-318.

Votanopoulos KI, Shen P, Stewart JH IV, Levine EA. Current status and future directions in appendiceal cancer with peritoneal dissemination. Surg Oncol Clin N Am. 2012;21(4):599-609.

All Publications

For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.

For a list of earlier publications, visit the Carpenter Library Publication Search.

Professor, General Surgery

Clinical Interests

Sarcoma, Hepatobiliary Surgery, Minimally Invasive Liver and Pancreatic Resection, Gastrointestinal Oncology Surgery, Peritoneal Surface Malignancies, Pancreatic Surgery, Melanoma
Perry Shen, M.D.

Perry Shen, M.D.

Program Director, Surgical Oncology
Professor, General Surgery
Comprehensive Cancer Center

Doctor Rating

4.6 out of 5

Perry Shen, M.D.214 Ratings
24 Comments

Doctor Ratings

The overall Patient Rating score is the average of responses to the nine questions listed below. The questions are from the Press Ganey Patient Satisfaction Survey. Responses are measured on a 1 to 5 scale, where 1 represents "very poor" and 5 represents "very good."
Press Ganey Patient Satisfaction Survey

CP concern for questions/worries
4.7
CP efforts to include in decisions
4.7
CP explanations of prob/condition
4.8
CP spoke using clear language
4.8
Friendliness/courtesy of CP
4.8
Likelihood of recommending CP
4.7
Patients' confidence in CP
4.8
Time CP spent with patient
4.6
Wait time at clinic
3.4



Patient Comments

Comments are taken from the Care Provider section of the Press Ganey Patient Satisfaction Survey. Comments are posted exactly as they are written. Comments are added weekly. To protect patient privacy and confidentiality, patient names are not included.

6/15/2015

Dr. Shen is a treasure. He is dedicated to providing the best care possible for his patients. I am tremendously grateful to him and his terrific team.

5/21/2015

I have been a patient of Dr. Shen's for 7 years now. He has been wonderful to me and my family and I have all the confidence in the world in him. He has saved my life.

4/30/2015

Excellent staff and care always top notch

4/1/2015

Dr.Shen has a great beside manner, Awesome Doctor.

2/27/2015

Dr. Shen is competent, compassionate, and easy to talk with. He is the greatest, and I am very grateful .

2/26/2015

With his kind manner and professional expertise, DR. Shen explains results of tests in a way as to alleviate any worries I may have.

1/30/2015

#10. We have told 2 people & they both have come to *Dr. Shen; the doctors (people make the hospital great!)

1/27/2015

Love Dr. Shen. He is always positive and caring.

1/5/2015

Dr Sheen like I said before, a very good caring person, a blessing many times over, in my surg. he done what needed to be done without making it more than was needed, we had planned for a long surg. but we wont know until we got in there, and as it turned out we were able to do the lesser. And also, Dr Sheen came around to check on you every day, and even came by one Sunday with his pretty daughter, made me think of my grand baby's and at that time I needed that reminding to get better, to get up, move around, you just can't lay there and that was what I needed at that time.

12/22/2014

I have only the up-most respect for *Dr. Shen. He is a most valuable dr. and surgeon to Baptist.

12/14/2014

I feel very fortunate to have been referred to Dr Shen. He is a wonderful surgeon and seems to be a very caring person.

12/3/2014

Good no problems.

10/30/2014

Dr. Perry Shen is an excellent care provider. He takes a personal interest in my health and my prognosis. It is comforting to know he is my physician.

10/28/2014

Dr. Shen addressed my medical condition without confusing me or making it sound worse than it is. The tumor is malignant and the abdominal hernia will need to be repaired by a general surgeon. This was explained to me and the appointments scheduled before I left the office at 5:10 pm. The support staff and residents reiterated what Dr. Shen told me.

10/28/2014

As I stated earlier, too many people in exam room and they had all my records, disc with scans and then asked me why I was there? Communication from my oncologist to Dr.Shen and others should have been clearer. They asked me what procedure I was looking to get. I think they should have known my cancer problems and reason I was there.

10/14/2014

Good.

10/14/2014

he did not ask me how long i thought it would be before i thought i was healed enough to return to the kind of work i do,He didn't ask me how i was feeling in the area that needed to be treated.

10/7/2014

*Dr. Shen is an excellent, surgeon & person - kind, compassionate & empathetic.

8/27/2014

Given the difficult circumstances, we could not imagine a better first meeting with Dr. Shen and his team. Very impressive.

8/27/2014

I feel that Dr. Perry Shen is a very good doctor and that I was fortunate to have been sent to him for the medical care that I needed.

8/26/2014

Very good

8/21/2014

Thank you. Great job by all.

8/18/2014

Dr Shen is always willing to answer my 16 year daughter guestions about my cancer. I love that !!!!

7/28/2014

Dr. Shen is the best! He takes a personal interest in my care and I trust him with all aspects on my cancer. He is always patient, kind and answers all my silly questions. Dr. Shen has saved my life, and there are no words to describe what he means to me and my family.

Quick Reference

Request an Appointment
New Patients

336-716-WAKE
888-716-WAKE

Existing patients may contact the clinic directly.
Find a Doctor Ways to Give
USNWR 2015-2016Magnet Hospital RecognitionConsumer Choice2014 Best DoctorsJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.